PMID- 21102497
OWN - NLM
STAT- MEDLINE
DCOM- 20120314
LR  - 20161125
IS  - 1476-5365 (Electronic)
IS  - 0268-3369 (Linking)
VI  - 46
IP  - 9
DP  - 2011 Sep
TI  - The outcome of high-dose chemotherapy and auto-SCT in patients with multiple 
      myeloma: a UK/Ireland and European benchmarking comparative analysis.
PG  - 1210-8
LID - 10.1038/bmt.2010.283 [doi]
AB  - Auto-SCT is the standard first-line consolidative therapy in patients with 
      multiple myeloma (MM). We performed a national benchmarking outcome analysis for 
      patients with MM who underwent a single auto-SCT in 1999 and 2005. They were 
      identified from the British Society of Blood and Marrow Transplantation (BSBMT) 
      (n=211 and n=453) and EBMT (n=1311 and n=1978) registries. An improvement in 
      Day+100 and D+365 non-relapsed mortality (NRM) was shown between years 1999 and 
      2005 (P=0.0495). The 4-year relapse rate (RR) was significantly higher in 2005 
      (P=0.0003) and was associated with a shorter time to next treatment (TTNT) 
      (P=0.025). The 4-year PFS was significantly lower in 2005 (P=0.0012), with the 
      year of auto-SCT (P=0.001) and status at auto-SCT (P=0.02) being independently 
      significant. The 4-year OS was similar between the year cohorts (P=0.266). In the 
      'benchmarking' comparison, the European Group for Blood and Marrow 
      Transplantation (EBMT) 1999 cohort demonstrated the best PFS, although no 
      year-of-transplant effect could be demonstrated on the 4-year OS rates (P=0.760). 
      An improvement in supportive care resulting in reduced NRM is evident between the 
      decades. The main cause of treatment failure remains disease progression. The 
      similarity in OS between the years may reflect the introduction of novel agents 
      in salvage therapy. The reduced PFS in 2005 is as yet not fully explained, but 
      may represent recent disease response criterion standardization.
FAU - Cook, G
AU  - Cook G
AD  - Department of Haematology, St James's Institute of Oncology, Leeds Teaching 
      Hospitals Trust, Leeds, UK. Gordon.Cook@leedsth.nhs.uk
FAU - Jackson, G H
AU  - Jackson GH
FAU - Morgan, G J
AU  - Morgan GJ
FAU - Russell, N
AU  - Russell N
FAU - Kirkland, K
AU  - Kirkland K
FAU - Lee, J
AU  - Lee J
FAU - Pearce, R
AU  - Pearce R
FAU - Marks, D I
AU  - Marks DI
FAU - Pagliuca, A
AU  - Pagliuca A
CN  - British Society for Blood and Marrow Transplantation (BSBMT)
LA  - eng
PT  - Journal Article
DEP - 20101122
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
SB  - IM
MH  - Adult
MH  - Aged
MH  - Combined Modality Therapy
MH  - Europe
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Ireland
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*drug therapy/*surgery
MH  - Treatment Outcome
MH  - United Kingdom
EDAT- 2010/11/26 06:00
MHDA- 2012/03/15 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2012/03/15 06:00 [medline]
AID - bmt2010283 [pii]
AID - 10.1038/bmt.2010.283 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2011 Sep;46(9):1210-8. doi: 10.1038/bmt.2010.283. Epub 
      2010 Nov 22.